The incidence of the primary endpoint events (including ischemic stroke, hemorrhagic stroke, and myocardial infarction cases) of CYP2C19 genotype-guided group decreased compared to the non-genotype-guided group, and so did the recurrence rate of ischemic stroke. This evidence concerns the gene CYP2C19 and ischemic stroke.